Author:
Saha Sudipto,Majumdar Sreyashi,Bhattacharyya Parthasarathi
Publisher
Springer Nature Singapore
Reference207 articles.
1. Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5(Suppl 2):S51–S55
2. Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H (2019) Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opin Pharmacother 20(1):95–102
3. Ahmed N, Bezabeh T, Ijare OB, Myers R, Alomran R, Aliani M, Nugent Z, Banerji S, Kim J, Qing G et al (2016) Metabolic signatures of lung cancer in sputum and exhaled breath condensate detected by (1)H magnetic resonance spectroscopy: a feasibility study. Magn Reson Insights 9:29–35
4. Ahmed N, Kidane B, Wang L, Nugent Z, Moldovan N, McElrea A, Shariati-Ievari S, Qing G, Tan L, Buduhan G et al (2022) Metabolic alterations in sputum and exhaled breath condensate of early stage non-small cell lung cancer patients after surgical resection: a pilot study. Front Oncol 12:874964
5. Akinboro O, Larkins E, Pai-Scherf LH, Mathieu LN, Ren Y, Cheng J, Fiero MH, Fu W, Bi Y, Kalavar S et al (2022) FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1-high NSCLC. Clin Cancer Res 28(11):2221–2228